Psoriatic Arthritis News
- BSR 2022 Risk Factors for COVID Death Studied in U.K. Arthritis Patients
- CARRA 2022 Prior Authorizations Delay TNF Inhibitors for Children With JIA
- AAD 2022 Dermatology Residency Focuses on Rural Placement of Graduates
- Alert Upadacitinib Earns FDA Approval for Ankylosing Spondylitis
- Hypocaloric Diet Controls Joint Activity in Psoriatic Arthritis
- AAD 2022 Apremilast's Effect on CVD Risk Markers Evaluated in Study
- Trial Gives New Guidance for Choosing Initial PsA Treatment
- CV Risk Biomarkers Tentatively Identified in Psoriatic Disease
- Methotrexate Plus Leflunomide Proves Effective for PsA
- Analysis: How Common Is Metabolic Syndrome in Patients With PsA?
- RWCS 2022 Health Disparities Exist Across Rheumatology: What Can Be Done?
- EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
- RWCS 2022 Patients Interrupting DMARD Use Well Into the COVID-19 Pandemic
- Ustekinumab Has Comparatively Low Infection Rate in IBD
- CRA 2022 Guselkumab Controls Axial Involvement in PsA Through 2 Years
- Dietary Recommendations for Inflammatory Rheumatic Diseases
- Alert FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis
- Risankizumab Effective Against Refractory Psoriatic Arthritis
- Case Series Show No Consensus on Treatment for Palmoplantar Pustulosis, Generalized Pustular Psoriasis
- Alert FDA Approves Secukinumab (Cosentyx) for Pediatric Arthritis